These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37622659)

  • 1. Dupilumab in the treatment of dystrophic epidermolysis bullosa: off-label use in a pediatric patient.
    Xará J; Relvas M; Figueiredo C; Calvão J; Batista M; Ramos L
    Int J Dermatol; 2023 Dec; 62(12):e617-e618. PubMed ID: 37622659
    [No Abstract]   [Full Text] [Related]  

  • 2. Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.
    Yang DY; Jing WW; Liu X; Li L; Lu T; Li XL
    Adv Skin Wound Care; 2024 Feb; 37(2):1-4. PubMed ID: 38241457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
    Vasilev P; Kalev D; Karamanliev M; Dimitrov D; Troyanova P; Yordanova I
    J Dtsch Dermatol Ges; 2023 Mar; 21(3):295-297. PubMed ID: 36855845
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab.
    Caroppo F; Milan E; Giulioni E; Belloni Fortina A
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e365-e367. PubMed ID: 34927769
    [No Abstract]   [Full Text] [Related]  

  • 5. Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report.
    Wang Y; Zhou M; Zhang L; Zheng S; Hong Y; Gao XH
    Dermatol Ther; 2021 Nov; 34(6):e15130. PubMed ID: 34528352
    [No Abstract]   [Full Text] [Related]  

  • 6. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa.
    Shao L; Zhong DQ; Liu YM; Wang JQ
    Int J Dermatol; 2023 Oct; 62(10):e542-e545. PubMed ID: 37326291
    [No Abstract]   [Full Text] [Related]  

  • 7. Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab.
    Yu L; Wang J; Bian L; Li Z; Li M; Li J; Zhang S
    Dermatitis; 2023; 34(1):58-59. PubMed ID: 36705654
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidermolysis bullosa pruriginosa treated with dupilumab.
    Zhou AG; Little AJ; Antaya RJ
    Pediatr Dermatol; 2021 Mar; 38(2):526-527. PubMed ID: 33336814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Control of Recalcitrant Pruritus in Epidermolysis Bullosa Pruriginosa With Dupilumab.
    Roque Quintana B; Piqué Durán E; Pérez Cejudo JA
    Actas Dermosifiliogr; 2024 Feb; 115(2):184-186. PubMed ID: 36871818
    [No Abstract]   [Full Text] [Related]  

  • 10. A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.
    Zhang L; Wang S; Chen Q; Xiang L
    J Dermatolog Treat; 2023 Dec; 34(1):2253943. PubMed ID: 37968922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa.
    Hunjan MK; Bardhan A; Harper N; Langman G; Ajayi B; Suresh V; Heagerty AHM
    Clin Exp Dermatol; 2022 Aug; 47(8):1588-1590. PubMed ID: 35426452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to 'A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab' by Caroppo et al.
    Martora F; Fabbrocini G; Nappa P; Marasca C; Patruno C; Scalvenzi M; Napolitano M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e729-e730. PubMed ID: 35604042
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
    Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
    Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of multicentric Castleman's disease associated with dystrophic epidermolysis bullosa using anti-interleukin-6 receptor antibody.
    Naruse S; Takashima S; Fujita Y; Kataoka H; Kawamura N; Natsuga K; Ujiie H
    J Dermatol; 2024 Aug; 51(8):e268-e269. PubMed ID: 38482904
    [No Abstract]   [Full Text] [Related]  

  • 15. Purified oral cannabidiol for pain management in severe recessive dystrophic epidermolysis bullosa.
    Welponer T; Diem A; Nahler G; Laimer M
    Indian J Dermatol Venereol Leprol; 2022; 88(4):551-552. PubMed ID: 35593277
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab.
    Shehadeh W; Sarig O; Bar J; Sprecher E; Samuelov L
    Br J Dermatol; 2020 Jun; 182(6):1495-1497. PubMed ID: 31899820
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
    Reimer A; Lu S; He Y; Bruckner-Tuderman L; Technau-Hafsi K; Meiss F; Has C; von Bubnoff D
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):e1-e3. PubMed ID: 31374134
    [No Abstract]   [Full Text] [Related]  

  • 18. Dominant dystrophic epidermolysis bullosa with congenital absence of skin and brachydactyly of the great toes.
    Sawka E; Funk T
    Pediatr Dermatol; 2021 Sep; 38(5):1251-1254. PubMed ID: 34338359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of epidermolysis bullosa pruriginosa by dupilumab.
    Wu XG; Yan S; Jiang JQ; Zhou TT; Fang X; Yang H; Bai XM; Wang H; Luo X
    J Dermatol; 2023 Jun; 50(6):837-842. PubMed ID: 36694424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases.
    Relvas M; Figueiredo AC; Calado R; Calvão J; Ramos L
    Dermatol Ther; 2022 Sep; 35(9):e15678. PubMed ID: 35770627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.